Alternative approaches to vaccine delivery

Wang, Lina; Chung, Charles Wai; Coppel, Ross L.

doi:10.4161/hv.6.1.9878

Cited by 3 publications

(2 citation statements)

References 79 publications

(92 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Transgenic animals have also been investigated as an alternative for recombinant protein production, mainly due to the possibility of producing large amounts of complex proteins in the milk [ 227 ]. In the context of vaccine production, two rotavirus proteins were produced in the milk of transgenic rabbits.…”

Section: Alternative Factories For Recombinant Vaccine Productionmentioning

confidence: 99%

Recombinant vaccines in 2022: a perspective from the cell factory

et al. 2022

View full text Add to dashboard Cite

The last big outbreaks of Ebola fever in Africa, the thousands of avian influenza outbreaks across Europe, Asia, North America and Africa, the emergence of monkeypox virus in Europe and specially the COVID-19 pandemics have globally stressed the need for efficient, cost-effective vaccines against infectious diseases. Ideally, they should be based on transversal technologies of wide applicability. In this context, and pushed by the above-mentioned epidemiological needs, new and highly sophisticated DNA-or RNA-based vaccination strategies have been recently developed and applied at large-scale. Being very promising and effective, they still need to be assessed regarding the level of conferred long-term protection. Despite these fast-developing approaches, subunit vaccines, based on recombinant proteins obtained by conventional genetic engineering, still show a wide spectrum of interesting potentialities and an important margin for further development. In the 80’s, the first vaccination attempts with recombinant vaccines consisted in single structural proteins from viral pathogens, administered as soluble plain versions. In contrast, more complex formulations of recombinant antigens with particular geometries are progressively generated and explored in an attempt to mimic the multifaceted set of stimuli offered to the immune system by replicating pathogens. The diversity of recombinant antimicrobial vaccines and vaccine prototypes is revised here considering the cell factory types, through relevant examples of prototypes under development as well as already approved products.

show abstract

Section: Alternative Factories For Recombinant Vaccine Productionmentioning

confidence: 99%

Recombinant vaccines in 2022: a perspective from the cell factory

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The stability of the protein in freeze dried leaves stored at room temperature demonstrates the potential of this technology to reduce barriers to vaccine delivery in resource‐constrained settings, where it is most needed. A review of this work has been recently published by the group (207).…”

Section: Alternate Immunization Strategiesmentioning

confidence: 99%

The Australasian contribution to malaria vaccine development

Redmond

Doolan

2010

Parasite Immunology

View full text Add to dashboard Cite

Malaria remains a major threat to public health worldwide, despite intense research efforts spanning decades. Much of this work has been directed towards developing an effective malaria vaccine, and scientists from Australasia have made significant contributions to progress in this area. Herein, we review the research undertaken in Australasia and summarize some of the important roles that Australasian researchers have played in malaria vaccine development that has occurred outside the region.

show abstract